Case studies
Landmark advances in outcomes for patients with heart failure Heart failure is a progressive and disabling condition associated with poor quality of life
The Robertson Centre of Biostatistics in the School of Health and Wellbeing has conducted a number of landmark randomised controlled trials of new treatments to improve survival and quality of life: CIBIS-II, CAPRICORN, CHARM series, VALIANT, BEAUTIFUL, SHIFT and EMPHASIS-HF. The trial results have been incorporated into clinical guidelines from the most prominent and influential cardiovascular societies, including: European Society of Cardiology and American College of Cardiology Foundation/American Heart Association. They have impacted on clinical practice and have been used by the pharmaceutical industry in regulatory approval applications from the European Medicines Agency and US Food and Drug Authority. Complementary research also encouraged the introduction of specialist heart failure nurses; preventing thousands of hospital admissions and saving the NHS £8 million per year.